Researchers from Dong Wha Pharmaceutical Co. Ltd. presented preclinical evaluation of a newly discovered histone-lysine N-methyltransferase EZH1/2 dual inhibitor, DW-91170, being developed for the treatment of lymphoma.
Immunogen Inc. scored a major win in top-line data from the confirmatory phase III trial called Mirasol evaluating the approved antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx, “mirv”) vs. chemotherapy in patients with folate receptor alpha-positive platinum-resistant ovarian cancer (PROC). The victory led shares of the Waltham, Mass.-based firm to close May 3 at $12.26, a rise of $7.06, or 135%.
Cellular Biomedicine Group Inc. (CBMG) licensed a pair of candidates for the treatment of non-Hodgkin lymphoma to Janssen Biotech Inc. for development outside of greater China. The candidates are anti-CD19 and CD20 bispecific CAR T-cell therapy C-CAR039 and anti-CD20 CAR T-cell therapy C-CAR066.
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway comprises four JAK kinases and seven STAT transcription factors. Among the latter, STAT3 is the best-known oncogene and its essential role in normal tissue makes its complete blockage useless for treatment due to severe side effects.
Idorsia Pharmaceuticals Ltd. has described C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Researchers at China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have divulged azaphenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
Previous studies have shown that ovarian cancer (OC) has strong tumor heterogeneity, resulting in high recurrence and metastasis rates. In recently published work, researchers from Capital Medical University (CMU) applied single-cell transcriptomics to identify metastasis-associated cell clusters and key genes involved in OC metastasis.
RSS
